Basic and clinical studies on BMY-28100 and its clinical evaluation in respiratory tract infections

Seuchi Aonuma, Kotaro Oizumi, Akira Watanabe, Masakichi Motomiya, Kiyoshi Konno, Kosaku Nagai

    研究成果: Article査読

    抄録

    We examined the in vitro antimicrobial activity of BMY-28100, a newly developed cephem antibiotic, by the broth dilution method using the MIC-2000 System. Minimum inhibitory concentrations (MICs) of BMY-28100 against 120 clinical isolates were compared with those of cefaclor (CCL) and cefixime (CFIX). Against Staphylococcus aureus, BMY-28100 was much more active than CCL and CFIX, but against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae and Pseudomonas aeruginosa, it was as active as CCL and much less active than CFIX. Twelve patients suffering from respiratory tract infection received orally 750mg or 1000mg of BMY-28100 a day. Clinical response was excellent in 1, good in 7, fair in 1 and poor in 3 patients. Mild anemia was observed in one patient.

    本文言語English
    ページ(範囲)214-221
    ページ数8
    ジャーナルChemotherapy
    37
    DOI
    出版ステータスPublished - 1989 1 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    フィンガープリント 「Basic and clinical studies on BMY-28100 and its clinical evaluation in respiratory tract infections」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

    引用スタイル